Tim Friede

After receiving perennial media attention over the 2000s and 2010s, he was contacted by immunologist and biotechnology researcher Jacob Glanville, who saw his acquired resistance as crucial to the development of a broad-spectrum snake antivenom. In a 2025 study published in ''Cell'', two of these antibodies, combined with the anti-inflammatory agent varespladib, proved effective in countering thirteen out of nineteen venoms in a sample of nineteen snake venoms, and was partially effective against the remaining six. He works as the director of herpetology at Glanville's biotechnology company, Centivax. Provided by Wikipedia